Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved entities : Bristol-myers squibb company save search
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Published: 2024-04-05 (Crawled : 14:00) - biospace.com/
TSVT | $3.87 -9.37% 87K
|
|
| O: 7.98%
H: 9.06%
C: -9.06%
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.41%
H: 0.51%
C: 0.25%
fda for therapy
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Published: 2024-04-03 (Crawled : 08:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.08%
H: 0.3%
C: -0.99%
reblozyl anemia approval treatment
U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
Published: 2023-08-29 (Crawled : 07:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.55%
H: 2.31%
C: 1.4%
reblozyl fda anemia treatment
Viz.ai Receives First De Novo Approval by the FDA for Hypertrophic Cardiomyopathy AI Algorithm
Published: 2023-08-15 (Crawled : 13:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.15%
H: 1.0%
C: 0.36%
fda approval
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
Published: 2023-07-21 (Crawled : 12:20) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.19%
H: 1.41%
C: 1.24%
melanoma chmp opdivo approval positive treatment
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer
Published: 2023-06-29 (Crawled : 13:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.5%
H: 1.06%
C: 0.36%
lung opdivo approval cancer cell treatment
U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.32%
H: 2.1%
C: 1.97%
camzyos drug label food positive study
Global Axial Spondyloarthritis Treatment Market to 2027: Increase in the Number of Approved Biosimilars Fuels the Sector
Published: 2023-06-16 (Crawled : 02:00) - prnewswire.com
UCBJY | $64.79 -0.72% 0
|
Manufacturing
|
| O: 1.21%
H: 0.0%
C: -0.2%
PFE | News 4 | $26.27 -0.19% -0.38% 130K
|
Health Technology
|
| O: 0.28%
H: 1.25%
C: 0.5%
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
|
| O: 0.46%
H: 0.31%
C: -0.15%
LLY | News | $732.2 -1.81% -0.71% 8K
|
Health Technology
|
| O: 0.41%
H: 0.26%
C: -1.77%
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.32%
H: 2.1%
C: 1.97%
approved treatment global market
Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts
Published: 2023-06-08 (Crawled : 22:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.28%
H: 0.42%
C: -0.05%
fda approval cell therapy
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
Published: 2023-05-03 (Crawled : 12:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.34%
H: 0.6%
C: -2.47%
breyanzi approval one cell therapy
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Published: 2023-03-28 (Crawled : 13:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.01%
H: 0.75%
C: 0.18%
AMGN | News | $271.635 -0.5% 120K
|
Health Technology
|
| O: 0.1%
H: 0.71%
C: 0.62%
approval psoriasis treatment
Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
Published: 2023-03-03 (Crawled : 14:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.25%
H: 0.09%
C: -0.09%
reblozyl anemia approval
U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
Published: 2022-09-10 (Crawled : 08:20) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $271.635 -0.5% 120K
|
Health Technology
| Email alert
Add to watchlist
treatment drug psoriasis food plague
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma
Published: 2022-07-22 (Crawled : 12:20) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: -0.41%
treatment melanoma antibody chmp approval positive nivolumab
Global Panic Disorders Market Insights | Size | Shares | Trends | Growth | Industry Analysis [2020-2030] Panic disorders, also known as anxiety disorder deals with recurrent and unexpected panic attacks. PET-CT Scanner Devices Market: Competitive Landscape Analysis With Forecast by 2031 Wilmington, Delaware: According to the report, the global PET-CT scanner devices market was valued over US$ 200 Mn in 2020 and is projected to expand at a CAGR of ~3% from 2021 to 2031. Portal Hypertension Market Insights | Current Trends | Growth Opportunity | Global Industry Analysis [2020-2030] At present, treatment options for portal hypertension is limited due to the dearth of approval of specialized drugs. Spatial Genomics & Transcriptomics Market to Experience Significant Growth by 2027 Wilmington, Delaware: The spatial genomics & transcriptomics market is prognosticated to bring profitable growth during the assessment period of 2019-2027. Teleradiology Services Market to Make Great Impact in Near Future by 2031 Wilmington, Delaware: According to the report, the global teleradiology services market was valued over US$ 6.4 Bn in 2020. Anti-depressants Drugs and Therapies Market to Witness a Pronounce Growth by 2025 Wilmington, Delaware: Anti-depressants medications lower the symptoms of depression, dysthymia, chronic depression, and anxiety disorders. B-Cell Non-Hodgkin’s Lymphoma (NHL) Market to Offer Ample Growth Opportunities by 2027 Wilmington, Delaware: Non-Hodgkin’s lymphoma is a group of heterogeneous proliferative malignancies. Heightening Healthcare Spending Opening Growth Avenues for Collateral Ligament Stabilizer System Market, Reaching US$ 3.5 Billion in 2032: Fact.MR Study Fact.MR – A Market Research and Competitive Intelligence Provider: The global collateral ligament stabilizer system market is expected to reach US$ 3.5 Billion by the end of the 2022-2032 forecast period, growing at a CAGR of 6.1%, concludes a recently published report by Fact.MR. Breast Cancer Liquid Biopsy Market Trends, Growth, Analysis and Future Scope, 2026 Wilmington, Delaware: A biopsy is a tissue or cell sample taken from any part of the patient’s body and examined in the lab for the detection of cancer. Cerebral Palsy Market Size, Shares, Trends and Growth | Global Industry Analysis [2020-2030] The global cerebral palsy market is picking up steam due to increasing awareness about the condition amongst parents. Continuous Glucose Monitoring Market: Competitive Research and Precise Outlook 2021 to 2028 Wilmington, Delaware: The global continuous glucose monitoring market depicts the presence of a large competitive vendor landscape, says Transparency Market Research on the basis of a newly research report. Crow’s Feet Market Key Trends and Opportunity Analysis up to 2026 Albany NY, United States: The demand within the global crow’s feet market has been escalating on account of vital advancements in the field of dermatology in recent times. HIV Associated Lipodystrophy Syndrome Market Insights | Global Industry Analysis [2020-2030] HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus -infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection. Global Mail Service Pharmacy Market | Size | Shares | Trends | Growth | Forecast [2020-2030]
Published: 2022-06-03 (Crawled : 06:00) - biospace.com/
GLAXF | News | $19.54 -3.77% 0
|
Health Technology
|
| O: -1.55%
H: 0.0%
C: 0.0%
SNYNF | News | $94.0 -0.27% 0
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
AZNCF | News | $135.35 400
|
Health Technology
|
| O: -0.4%
H: 4.05%
C: -1.35%
PFE | News 4 | $26.27 -0.19% -0.38% 130K
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
GSK | News | $40.93 0.17% 170K
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% -0.71% 8K
|
Health Technology
|
| O: -2.25%
H: 0.0%
C: 0.0%
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 220K
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
NBIX | News 4 | $138.97 -0.8% -0.85% 17
|
Health Technology
|
| O: 2.29%
H: 0.0%
C: 0.0%
AZN | News | $75.37 5.86% 2.7M
|
Health Technology
|
| O: -0.56%
H: 0.82%
C: -0.64%
lipodystrophy treatment research system active services report service growing hiv profitable hypertension genomics expected virus approval cancer growth group market breast cancer infections
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-05-03 (Crawled : 18:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.23% 690
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
EXEL | $23.515 -0.82% 100K
|
Health Technology
|
| O: 0.09%
H: 1.54%
C: -0.44%
cabometyx approval cancer
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%
Published: 2022-04-05 (Crawled : 12:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.04%
H: 1.67%
C: 0.91%
treatment opdivo approval nivolumab urothelial carcinoma
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
Published: 2022-04-05 (Crawled : 12:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.04%
H: 1.67%
C: 0.91%
treatment opdivo approval nivolumab
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
Published: 2022-04-05 (Crawled : 12:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.04%
H: 1.67%
C: 0.91%
treatment opdivo approval nivolumab
Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2021-11-23 (Crawled : 12:30) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -1.0%
H: 0.0%
C: 0.0%
europe approval ulcerative colitis
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
BOF | $1.915 63.68% 620K
|
AMST | $3.13 56.5% 500K
|
Technology Services
ACON | $0.3595 24.83% 3.5M
|
n/a
CDTX | News | $14.57 18.55% 330K
|
Health Technology
ULBI M | $10.12 15.92% 120K
|
Producer Manufacturing
LRHC | $1.79 11.88% 3K
|
n/a
AIXI | $1.34 8.94% 42K
|
n/a
TRU | $74.475 8.44% 100K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.